This article is a correction to:
Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review
Yanqi Ye
Chun Xu2*
Fengqian Chen
Qi Liu
Ning Cheng- 1Zenomics. Inc. Magnify at California NanoSystems Institute, Los Angeles, CA, United States
- 2School of Dentistry, The University of Queensland, Brisbane, QLD, Australia
- 3School of Medicine, University of Maryland, Baltimore, MD, United States
- 4School of Medicine, Johns Hopkins University, Baltimore, MD, United States
- 5Department of Otolaryngology - Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, United States
A Corrigendum on
Targeting innate immunity in breast cancer therapy: a narrative review
by Ye Y, Xu C, Chen F, Liu Q and Cheng N (2021) Front. Immunol. 12:771201. doi: 10.3389/fimmu.2021.771201
In the published article, there was a missing citation of “The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy, doi.org/10.3389/fonc.2021.610303”in the legend for Figure 1 as published. The corrected Figure 1 legend appears below.
Figure 1
Figure 1 Breast cancer microenvironment is populated by diverse infiltrating immune cells. These immune cells are categorized into immunosuppressive population and immunostimulating population (e.g.) according to their major characteristics in modulating breast cancer. The immunosuppressive cells include polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), monocytic MDSC (Mo-MDSC), regulatory T cells (Treg), mast cells (MC), M2-like macrophages and type 2/3 innate lymphoid cells (ILC 2/3). The immunostimulating cells include tumor infiltrating lymphocytes CD8+ and CD4+ T cells, nature killer cells/type 1 innate lymphoid cells (NK/ILC1), dendritic cells (DCs) and eosinophils. This figure is reproduced with permission from “The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy, doi.org/10.3389/fonc.2021.610303” Copyright ©2021 Frontiers.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: innate immunity, breast cancer, cancer immunotherapy, clinical studies, vaccine adjuvants
Citation: Ye Y, Xu C, Chen F, Liu Q and Cheng N (2023) Corrigendum: Targeting innate immunity in breast cancer therapy: a narrative review. Front. Immunol. 14:1353708. doi: 10.3389/fimmu.2023.1353708
Received: 11 December 2023; Accepted: 12 December 2023;
Published: 20 December 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Ye, Xu, Chen, Liu and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chun Xu, chun.xu@uq.edu.au; Ning Cheng, Ning.Cheng@ucsf.edu